Evolving understanding and current management of patients with cancer of unknown primary site

Community Oncology

Volumn 7, Issue 4, 2010, Pages 183-188

  Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER SCREENING; CLINICAL FEATURE; DIAGNOSTIC TEST; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT ASSESSMENT; PATIENT CARE; PROSTATE CANCER; SYSTEMIC THERAPY; TUMOR LOCALIZATION;

EID: 77952908807     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70301-1     Document Type: Article

References (15)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott; 2008:2363-2387.
2. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome, the Systematic literature review. Cancer Treat Rev 2009;35:221-227.
3. Owen KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36,8-37.
4. Bender RA, Erlander MG. Molecu lar classification of unknown primary cancer. Semin Oncol 2009;36:38-43.
5. Greco FA, Erlander MG. Molecular classification of cancers of unknown primary site. Mol Diagn Ther 2009;13:367-373.
6. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009;36:35-74.
7. Greco FA. Therapy of adenocarcinoma of unknown primary: are we making progress? J Natl Compr Canc Netw 2008;6:1061-1067.
8. Varadhachary GR, Talantov D, Rayber MN, et al. Molecular profiling of carcinoma of unknown primary in correlation with clinical evaluation. J Clin Oncol 2008;26:4442-4448.
9. Horlings HM, van Laar RK, Kerst JM, et al. Gene expression profiling to identify the histogenic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26:4435-4441.
10. Bridgewater J, van Laar RK, Floore A, van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 2008;98:1425-1430.
11. Monzon FA, Henner WD, Medeiros F. Use of microarray-based 1550-gene expression profile of carcinoma of unknown primary (CUP). Gastrointestinal Cancer Symposium. American Society of Clinical Oncology; January 15-17, 2009; San Francisco, Calif. Abstract 313.
12. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.
13. Rosenfeld N, Aharonov R, Meiri E, et al. Micro RNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469.
14. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009;27:2503-2508.
15. Greco FA, Spigel DR, Yardley DA, et al. Unknown primary cancer (UPC): accuracy of tissue of origin prediction by molecular profiling. J Clin Oncol 2009;27(15S):11070.